Piper Jaffray launched coverage of Canopy Growth (NYSE:CGC; TSX:WEED) with an “overweight” rating and $40 price target. The stock was quoted at $32.16, up $2.52, around midday on Jan 9. “While it is difficult to...

Ladenburg Thalmann launched coverage of Millendo Therapeutics (NASDAQ:MLND) with a “buy” rating and $29 price target. The stock closed at $7.65 on Jan. 3. Millendo is a clinical-stage company focusing on the development...

Canaccord Genuity launched coverage of Chembio Diagnostics (NASDAQ:CEMI) with a “buy” rating and $9 price target. The stock closed at $5.48 on Jan. 3. “In our opinion, Chembio is an underappreciated player in the...

H.C. Wainwright initiated coverage of Synthorx (NASDAQ:THOR) with a “buy” rating and $30 price target. The stock closed at $17.38 on Dec. 31. Synthorx’s Expanded Genetic Alphabet (EGA) technology generates a modular...

Dawson James initiated coverage of ADMA Biologics (NASDAQ:ADMA) with a “buy” rating and $7 price target. The stock closed at $2.34 on Dec. 27. ADMA is focused on bringing a high-value, potent intravenous immunoglobulin...

H.C. Wainwright initiated coverage of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) with a “buy” rating and $24 price target. The stock closed at $5.26 on Dec. 24. The company’s lead compound, lenabasum, is a...

H.C. Wainwright launched coverage of NeuroMatrix (NASDAQ:NURO) with a “buy” rating and price target of $5. The stock closed at 68 cents on Dec. 24. NeuroMetrix is a healthcare technology company that has two products on...

H.C. Wainwright initiated coverage of Translate Bio (NASDAQ:TBIO) with a “buy” rating and $21 price target. The stock closed at $8.05 on Dec. 24. Translate Bio is developing treatments for diseases caused by an absence...

H.C. Wainwright initiated coverage of AnaptysBio (NASDAQ:ANAB) with a “buy” rating and price target of $126. The stock closed at $60.54 on Dec. 19. While AnaptysBio has emerged as a newcomer in the competitive field of...

H.C. Wainwright launched coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with a “buy” rating and $18. The stock closed at $5.27 on Dec. 19.

H.C. Wainwright initiated coverage of Sunesis Pharmaceuticals (NASDAQ:SNSS) with a “neutral” rating and price target of 50 cents. The stock closed at 32 cents on Dec. 19.

Ladenburg Thalmann launched coverage of Cerecor (NASDAQ:CERC) with a “buy” rating and $9 price target. The stock closed at $3.18 on Dec. 19.

H.C. Wainwright initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “buy” rating and price target of $18. The stock closed at $5.73 on Dec.19. Dova is developing a new thrombopoietin receptor alpha agonist...

H.C. Wainwright launched coverage of Unum Therapeutics (NASDAQ:UMRX) with a “buy” rating and $18 price target. The stock closed at $4.47 on Dec. 19.

H.C. Wainwright initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and $10 price target. The stock closed at $2.11 on Dec. 19.

Stifel downgraded DBV Technologies (NASDAQ:DBVT) to “hold” from “buy” and slashed its price target to $11 from $35 after the company withdrew the BLA for its Viaskin peanut allergy treatment after a meeting with the FDA...

Dawson James initiated coverage of Brainstorm (NASDAQ:BCLI) with a “buy” rating and $12 price target. The stock closed at $3.05 on Dec. 17. Brainstorm uses autologous cell therapy to treat amyotrophic lateral sclerosis...

Mackie Research Capital established a price target of $10.50 for Medexus Pharmaceuticals (TSXV:MDP) following a 15-for-one reverse stock slated for completion on Dec. 19. Medexus, formerly Pediapharm (TSXV:PDP) also...

Ladenburg Thalmann initiated coverage of Novavax (NASDAQ:NVAX) with a “buy” rating and $3 price target, as “we look for transformational data in the first quarter of 2019.” The stock closed at $2.27 on Dec. 17. Novavax...

H.C. Wainwright downgraded Advaxis (NASDAQ:ADXS) to “neutral” from “buy” and removed its price target after Amgen terminated a development and collaboration agreement on ADXS-NEO, Advaxis’ personalized neoantigen...

Roth Capital Markets launched coverage of CollPlant Holdings (NASDAQ:CLGN) with a “buy” rating and 12-month price target of $7. The stock closed at $4.36 on Dec. 17. CollPlant is the world’s first and only commercial...